<unk>  is a antineoplastic agent that is FDA approved for the treatment of treatment of multiple myeloma in combination with lenalidomide and dexamethasonein patients who have received at least one prior therapy.   Common adverse reactions include thrombocytopenia, gastrointestinal toxicities, peripheral neuropathy, peripheral edema, cutaneous reactions, and hepatotoxicity.
Ixazomib
Carfilzomib
Bortezomib
Idoxuridine
Carmustine 
Ifosfamide
Busulfan 
Lenalidomide